TrialPulmonary pharmacology & therapeutics2023

Patients with moderate to severe COVID-19 outcomes on remdesivir according to baseline 4C mortality score.

Jacob Sellers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.